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1.0 Introduction 
 
The requirement to provide effective methods of drug delivery whilst minimising risk to patients 
(and clinicians) is an age old challenge and there is little doubt that the field has improved 
dramatically in the modern era. It is not, however, free from issues and there remain 
considerable concerns that relate to the possible adverse effects that can be experienced by the 
patient should the delivery mechanism fail. Leaving aside the direct toxicological properties of 
the drug itself, and its possible adverse effects, there are a multitude of chemical and biological 
safety concerns relating to the actual delivery process that pose considerable technological and 
procedural challenges to healthcare providers[1-3]. The use of injection (subcutaneous, 
intramuscular or intravenous) is one of the most common approaches to drug administration 
but it is also a method which has a long history of issues that relate to chemical and biological 
safety [2,3]. As a consequence, there has been a substantial effort to develop new microneedle 
methods of drug delivery which avoid many of the safety issues presently associated with 
conventional routes.  
 
Over the past decade, the use of transdermal patches and microneedles has garnered 
considerable interest and these have begun to reach levels of sophistication where so called 
“smart patches” are being designed to offer controlled, personalised, dosage profiles[4-8]. The 
level of interest in the development of these new, transdermal systems is emphasized by recent 
market estimates valuing the current sector at $31.5bn with around 12% of the global drug 
delivery market being dedicated to transdermal formulations[9]. Moreover, there are some 700 
clinical trials relating to transdermal delivery registered by the National Institutes of Health 
(NIH) [10]. It must be acknowledged that such figures constitute a wide spectrum of transdermal 
drug delivery routes – from topical gels to more elaborate microelectromechanical devices.  
Despite such advances, there are many questions as to whether such systems will provide 
answers to the issues of safety or whether they may, in fact, present some new ones.  
 
While conventional parenteral drug administration mechanisms are primarily mechanical in 
nature, the transdermal routes are more reliant on chemical transformations and, as such, raise 
a number of inherent safety concerns. This report does not consider the detailed chemistries 
and pharmaco-kinetic efficacy of the release systems, rather, the aim is to provide an overview 
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of the new smart microneedle based patch technologies, highlight the possible factors that can 
give rise to issues over chemical safety and critically assess their ability to provide a truly safer 
approach to drug delivery. 
 
2.0 Conventional Delivery – Issues and Practicalities 
 
Oral administration forms the most common route of administration with the ease of use, lack 
of invasiveness and the possibility of self-administration accounting for its popularity within the 
healthcare industries. The delivery process is straightforward and, while the drug itself may 
possess aggressive properties such as gastrointestinal inflammation or tissue/organ toxicity at 
high doses, the binder/encapsulant used to deliver the drugs themselves are relatively benign.  
The approach is not suitable for all drugs however, with the tendency for a drug’s performance 
to become degraded by the effects of hepatic first-pass metabolism which often requires higher 
dosage with the consequent exacerbation of side effects [4-6]. There are also issues with patient 
compliance where the need for repeat dosing can lead to variations in dose administration 
which will inevitably lead to undesirable spikes and troughs in the concentration of the drug 
within the systemic circulation [11, 12]. Missed or erroneous multiple dosing, caused either by 
accidental forgetfulness or by conditions such as dementia or Alzheimer’s [13,14], is an increasing 
safety concern and there has been a raft of ancillary products designed to aid adherence to 
dosing regimes – from simple pill boxes to smart phone apps[15,16]. 
 
Hypodermic injections comprise the second most common approach to drug delivery however, 
like oral administration, it is not without some inherent issues. The associated pain and fear of 
injection (needle phobia) can significantly impact on patient compliance [6, 17]. A much more 
serious limitation relates to unsafe injection practices where, it has been estimated, there are 
approximately 874 million cases worldwide per annum. There can be a perception that unsafe 
injection practices frequently stem from the developing world and, in some cases, the re-use of 
unsterilized equipment within the latter can be commonplace [18]  but, it is important to 
recognise that it is an issue that persists in first world countries[19-25]. Improper usage and unsafe 
administration is linked, but not limited to, the reuse of needles with the consequent spread of 
infection or disease. Needlestick injuries are a constant hazard irrespective of clinical expertise 
and the safe disposable of sharps and associated waste can be problematic [20, 22,23]. It has been 
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estimated by the World Health Organisation that of the 35 million global health-care workers, 2 
million experience percutaneous exposure to infectious diseases (Hepatitis B (37.6%), Hepatitis 
C (39%) and HIV(4.4%)) each year [23]. 
 
Leaving the potential for blood borne virus and infection aside, the apparently simple process of 
injection practice can also contribute to safety concerns and the reuse of insulin needles is a 
particularly contentious example. Repeated needle reuse is relatively common within the 
diabetic population but there are worries from manufacturers and clinicians alike that it can 
lead to deformation of the needle tip which increases tissue scarring (lipodystrophy) and can 
increase the risk of metallic fracture and fragments being left in the skin [26,27].  
 
3.0 Transdermal Delivery 
 
The main advantage of hypodermic needle delivery is the ability to avoid gastrointestinal 
degradation and first pass metabolism which would otherwise reduce the therapeutic yield but 
there are alternatives. The first transdermal patch delivery system, for the anti-sickness drug 
scopolamine, gained regulatory approval in 1979 and heralded a significant advancement in 
non-invasive drug delivery [12].  Since its introduction there has been a steady commercialisation 
of transdermal patches as (indicated in Table 1 within the supporting Information). It is now 
possible to obtain a number of preparations as an over the counter (OTC) product with nicotine 
patches arguably being among the most common. In the majority of cases, the delivery process 
is achieved through passive diffusion across the skin but, while the latter presents a highly 
accessible and relatively vast surface area, its barrier properties have presented significant 
hurdles to the passive transport of drugs to systemic circulation [4-6]. This partly explains the 
relatively small number of products available when compared to those delivered through 
conventional routes. The basic schematic of a conventional transdermal patch found in 
pharmacies is highlighted in Figure 1.  Potential transdermal drug candidates must possess a 
sufficiently low molecular weight (less than 500 Da) along with both adequate hydrophilic and 
lipophilic properties (Log P (octanol / water partition coefficient) of 3-5) to enable penetration through the 
stratum corneum and subsequent epidermal layers [28].  
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In order to overcome such limitations, the patch systems have begun to evolve from exploiting 
simple passive delivery methods, through to more aggressive means of disrupting the structure 
of the epidermis to increase porosity. The use of chemical enhancers, heat, electroporation, 
iontophoresis, ultrasound, thermal ablation, and dermabrasion methods have, and continue to 
be, investigated as routes through which to disrupt the epidermal layers and allow the passage 
of larger molecules[4-8].  There are obvious safety issues associated with the implementation of 
such methods – the possibility of irritant dermatitis arising from the use of chemical enhancers 
is an obvious concern [29]. The use of cavitational ultrasound and thermal ablation methods also 
carry concerns over tissue damage [30]. In any event, the majority of these systems are largely 
restricted to clinical research environments and their translation to commercial mainstream 
products that can be readily administered to patients is severly restricted by the complexity and 
cost of their implementation. In many respects, such methods have been largely overshadowed 
in recent years with an ever growing interest in the use of microneedle designs [7-8]. This has 
spurned a large number of different design and material approaches and it is upon these, and 
their chemical safety implications, that the authors wish to train a spotlight.  
 
4.0 Microneedles 
 
The concept of using microneedles as a delivery system stems from 1976 and was viewed as a 
means of combining the benefits of transdermal and hypodermic methods in a way that would 
be much more efficient than the former whilst being acceptable to the patient [31]. In recent 
studies investigating user perceptions and experience of microneedles, it was notable that the 
majority of respondents described the application of the latter as ‘pressing,’ or ‘heavy’ in 
comparison to the ‘sharp’ and ‘stabbing’ feeling experienced with conventional hypodermic 
injections [31]. In principle, it could be anticipated that, through physically puncturing the stratum 
corneum, the range of drugs capable of being delivered through passive patch technologies 
could be dramatically expanded. The latter are severely restricted as a consequence of the 
molecular weight and lipophilic requirements necessary to enable passive but, in creating 
microchannles that bypass the hydrophobic skin barrier, larger, hydrophilic molecules could be 
readily transferred direct to the microcirculation. The challenge at present relates principally to 
the delivery of large polypeptides or nucleic acids which would otherwise fail to traverse the SC 
using traditional transdermal methods [7, 8]. 
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Since their inception, there have been a multitude of design geometries married to an ever 
increasing range of materials [32,33] but, irrespective of design and fabrication method, they all 
consist of a base plate upon which a field of micron sized projections (50-900 mm) are arranged 
[33]. Breaching the SC layer simply through “thumb pressure” administration of the patch to the 
skin stands in marked contrast to the instrumentational complexity and costs inherent to the 
dermal poration methods mentioned previously. Moreover, the needles are sufficiently short to 
avoid triggering dermal nerves with recent studies, comparing the skin sensation of applying a 
flat baseplate with that of a microneedle patch, finding that only 20% of volunteers could 
distinguish between the two [34]. 
 
Five basic approaches to the design of microneedle drug delivery systems have evolved over the 
past decades and are based on: solid, coated, hollow, dissolvable and swellable formulations. 
Their modes of operation are summarised in Figure 2 and their features and safety issues 
described briefly in the following subsections.  
 
4.1 Solid Microneedles 
 
Historically, solid microneedles were the first to emerge and their implementation as a drug 
delivery route is commonly referred to as a “poke and patch” approach. Microneedles based on 
silicon, stainless steel or titanium are applied to the skin (as a discrete patch, punch or roller) 
and are responsible for physically creating micron sized channels in the SC [35-38]. Under non 
occlusive conditions, the barrier function of the SC is typically restored within 2 hours of the 
original treatment [39,40] but the pore lifetime can be extended through chemical manipulation: 
diclofenac and fluvastatin have been shown to delay closure by 7 days when used as a co-eluting 
drug [41,42]. The subsequent application of a drug formulation (gel, cream, swab or spray) to the 
micropunched site allows the therapeutic agent to access the pores and transfer to the 
underlying microcirculation relatively unimpeded. The two step process is however procedurally 
cumbersome and the topical delivery of the drug through manual manipulation can be 
inefficient and economically wasteful when considering high value vaccines or gene therapies [43, 
44]. 
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4.2 Coated Microneedles 
 
The development of solid microneedles coated with the therapeutic agent was an attempt to 
push earlier approaches towards a single application system that would be much more suitable 
for patient use.  In this case, the drug is coated directly onto the needles using conventional dip 
or spray coating procedures relying largely on physico-chemical adsorption and avoids any 
complicated chemical manipulation or surface modifications [45-48]. Upon breaching the SC layer 
the drug molecules simply dissolve into the surrounding tissue and diffuse to the 
microcirculation. Although offering a one-step procedure, the dosage will depend on the active 
microneedle area onto which the drug can be coated and, as such, the total yield can be 
considerably limited and restricted to drugs with a low yield-high potency profile (ie. antigenic 
material / RNA) [49, 50].  
  
It is little surprise therefore to find that the use of coated microneedles has found a particular 
niche in the delivery of vaccines [51-61]. The presence of a significant population of antigen 
presenting cells (APCs) within the outer skin layers enables a strong immune response to be 
obtained from the delivery of small amounts of immunogenic material [62] resulting in 
comparable or superior performance to conventional subcutaneous and intramuscular 
injections[57-59]. Critically, the approach assuages many of the safety concerns associated with 
needles and avoids issues of patient phobia – especially when considering the vaccination of 
children [63]. This is supported by recent studies where the availability of a self-administered 
microneedle patch was found to increase the intent to be vaccinated from 44 to 65% when 
compared with the standard injection modes [64]. 
 
One potentially critical advantage of the microneedle approach towards vaccinations relates to 
long term storage. The latter has been, and continues to be, a considerable problem with the 
cold storage requirements necessary to preserve the antigen often hindering decentralised 
vaccination – particularly in remote locations [65]. Many of the approaches taken with the 
microneedle system employ dry formulations which help overcome the refrigeration limitations. 
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Studies by Kommareddy et al. (2013) demonstrated that microneedles coated with the influenza 
subunit vaccine and stored at room temperature in a desiccated environment remained viable 
for 8 weeks [57]. 
 
4.3 Hollow Microneedles 
 
Hollow microneedles (HMN) were principally intended to overcome the dosage limitations 
inherent to coated solid systems whereby the design mimics that of a conventional hypodermic 
syringe – albeit on a greatly smaller scale [62, 67-70]. The HMN are used in conjunction with a drug 
reservoir typically allowing up to 200 mL of therapeutic agent to be released [69]. The fabrication 
processes are significantly more complex and it must also be noted that the move towards 
hollow needles with a high aspect ratio can also impair the mechanical properties of the 
structure leading to failure if improperly inserted (discussed in later sections). The situation can 
be further compounded by blockage of the needle bore with dermal tissue during the insertion 
process resulting in a much reduced release efficiency [70]. 
  
4.4 Dissolvable Polymer Microneedles 
 
Dissolvable microneedles are a much more recent development and typically involve the 
incorporation of the drug within the polymer framework used to form the needle structure [71-
76]. The dissolution of the polymer releases the entrapped drug and an example is highlighted in 
Figure 3.  The main limitation however is that the delivery yield can be overly restrictive and it is 
important to appreciate that the primary drug delivery component is the needle structure and 
not the supporting base plate [33]. This necessitates that a compromise is reached between drug 
yield and the amount of polymer necessary to ensure the mechanical integrity of the needle 
structure. The larger the size of the drug – the lower the concentration which can be reliably 
delivered. A secondary concern relates to the processing requirements for the formation of the 
microneedle and compatibility with the therapeutic agent. High temperatures, solvents, 
extreme pH profiles can significantly affect the viability of protein and vaccine based drugs.  
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4.5 Swellable Microneedles 
 
These are typically based on a hydrophilic hydrogel framework which absorbs fluid from the 
surrounding tissue and physically swells creating pores/nanochannels within the needle through 
which the drug can diffuse [43]. In contrast to the dissolvable MN system, drug molecules 
contained within the baseplate can be efficiently transferred through the needle to the 
surrounding tissue. The rate at which transfer occurs can be finely tuned through manipulating 
the number of crosslinks within the hydrogel structure.  
 
5.0 Microneedle Safety: Features and Concerns 
 
The stratum corneum’s prime role is to serve as an efficient barrier regulating water loss and 
preventing the ingress of contaminants and therefore any material that physically breaches the 
wall to allow material to pass, relatively unhindered, to the microcirculation and beyond will 
inevitably raise concerns. Much of the initial safety evaluation and patient assessments have 
been conducted in relation to solid microneedle systems and there are many favourable aspects 
to their implementation when compared with conventional injection systems. It has been shown 
that for solid microneedle systems, the channels are closed within a few hours of the original 
injury and that normal skin function is restored with typically no sustained erythema following 
their removal [39, 40]. The use of silicon, stainless steel and titanium are relatively benign from a 
biocompatibility perspective and there are few issues in relation to irritant contact dermatitis 
[39].   
 
One particular concern has been the fact that microchannels can create a highway through 
which bacteria can gain access to the underlying tissues however, in general, the possibility of 
infection can be greatly minimised by good clinical practice. The application of antibacterial 
wipes (alcoholic chlorhexidine etc.) prior to exposure is a standard procedure and can preclude 
the influx of adventitious species present within the surrounding skin. It must also be noted that 
there have been a number of studies that have shown that the potential for infection after 
microneedle exposure is markedly less than that with conventional injection methods [77, 78]. The 
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use of polymer microneedles brings some unique properties that can further minimise the 
possibility of infection. There is an increasing interest in the use of polymers possessing an 
inherent antibacterial action (i.e. those with quaternary nitrogen atoms/heterocyclic structures) 
to provide the needle framework within which the drug is either coated or encased and thereby 
acts to actively counter any microbes that have been accidently drawn into to the channels as a 
consequence of the application procedure or their subsequent influx [79]. 
 
The US Needlestick Safety and Prevention Act (2000) requires that sufficient training in the use 
of safe procedures and appropriate personal protective equipment is provided and devices for 
rendering contaminated sharps into a safe form after use (ie needle encapsulation 
covers/attachments) are readily available24. Despite such provisions, the prevalence of such 
injuries are an ever present concern within hospital and community healthcare.  A survey by the 
American Nursing Association into the causes and frequency of needlestick events found that 
most occur during injection (28%), before applying the safety enclosure (19%) or during disposal 
of the needle (19%).  It was also reported that 64% of the respondents reported being accidently 
struck by a needle [20]. Bilateral injuries are a significant cause of needlestick and arise 
predominantly as a consequence of applying the normally prescribed method of a skin “pinch” 
whereby a raised fold of skin is created between the thumb and forefinger of the non dominant 
hand prior to the administration of a subcutaneous injection [21]. Such practices run the risk of 
the needle travelling through the skin fold into the finger of the healthcare worker with the 
subsequent withdrawal of the needle resulting in the potential exposure of each to the blood of 
the other. It has been estimated that the latter accounts for 1 in 30 injection injuries [21].  
 
It could be envisaged that there remains a potential hazard for needlestick injuries to occur with 
the microneedle patches through the careless handling of the patch pre and post application 
and this would certainly be a cause for concern where solid (Si, Steel or Ti) needles are 
employed. The lack of sensation associated with their application could be particularly 
dangerous where accidental puncture occurs as there will be little in the way of warning to the 
healthcare worker that a potential needlstick injury has occurred. The use of dissolvable 
microneedles however, presents a truly innovative solution which greatly reduces the risk of 
post needlestick injury. In this case, the micro projections that constitutes the “sharp” hazard 
are effectively destroyed in the process of delivering the drug/vaccine[1-3]. It could also be 
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envisaged that swellable needle systems will also markedly reduce post stick injuries as the 
hydrated form will have lost much of the mechanical rigidity necessary for skin puncture. This 
automatic self-disabling mechanism is a critical safety feature as it is found that some 6% of 
needlestick injuries arising from hypodermic injection arise from attempts to engage the safety 
enclosure [20]. 
 
Most countries will have legislation in place to mandate the safe disposal of hypodermic 
syringes and associated sharps but there is little doubt that the volume of waste associated with 
conventional devices creates an economic burden for healthcare administrators. One example 
of the magnitude is given by Emmanuel and colleagues (2004) in which it was reported that a 
relatively small vaccination campaign in the Philippines gave rise to over 130 tonnes of sharps 
waste [80]. Clearly, the small size of the microneedle patches would dramatically counter such 
volumes. Moreover, the dissolution of the “sharp” component in the case of dissolvable and 
swellable polymer formats would undoubtedly ease the post use disposal processing.   
 
One of the core selling points in relation to microneedles, irrespective of design, is the ease with 
which they can be applied. While it is true that the near invisible nature of the needle array can 
instantly remove apprehension, there are concerns over the possibility of ineffectual application 
and administration [81,82].  Microneedles can be self-administered through “thumb pressure” or a 
“snap” applicator but there can be little indication that the needles have indeed pierced the SC. 
Recent investigations have shown that thumb pressure application is successful in almost 90% of 
cases, nevertheless there was often a need for multiple attempts and instruction to increase the 
success rate [81, 82].  It must be acknowledged that microneedles intended for skin puncture will 
be subject to a wide range of mechanical stresses. Variations in skin morphology can lead to 
non-uniform insertion of the microneedle array and can induce sheer stresses and transverse 
bending of the microneedles [83, 84]. Random movements during the manipulation of the patch 
assembly during insertion and removal, especially where there are multiple attempts, will 
inevitably result in axial compression and sheer stresses which may lead to the failure and 
fracture of the needles [85-88]. It is also important to note that the baseplate which forms the 
foundation of the patch can also be subject of bending forces which, if not sufficiently flexible, 
can fracture [89]. It has been shown that a decrease in the microneedle height provides a more 
favourable safety margin[83].  
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The relatively painless application is clearly an advantage but it can also be a limitation where 
there is uncertainty over whether not the microneedles have been successful in delivering their 
load.  There is a need for some form of feedback mechanism to alert the patient (or clinician) 
that the microneedle has successfully deployed and that the needles have penetrated to the 
correct depth [81, 82]. Such issues are of paramount importance in the case of vaccine delivery 
where there is an ever increasing interest in the use of microneedles and the consequences of a 
false positive could be life threatening. At present, many of the preliminary investigations utilise 
dyes (typically methylene blue[90,91]  or trypan blue[92,93]) as model drugs where delivery to the 
skin and the subsequent puncture can be easily visualised by the transfer. Moreover, they are 
known to selectively stain living cells within the epidermis and not simply the top most layers of 
the SC and can be used as gauge for the creation of microchannels [88]. It could be anticipated 
that the inclusion of an inert (biodegradable) dye within the actual drug loaded patch could go 
some way to providing an immediate feedback indication for successful delivery.    
 
It has been noted that the time from puncture to recovery in terms of solid microneedle is of the 
order of several hours but there is little information on the closure profile where polymer 
fragments are left to transcend the skin barrier. The fast healing of the microchannels are a 
major factor in minimising the possibility of infection but the failed removal of a swellable 
microneedle may end up serving as a longer lived conduit to the underlying tissue. At present 
there is a dearth of studies that can consider the mechanical failure of such systems and the 
consequences for restoring skin integrity. 
  
The increasing interest in the use of polymer microneedles in the form of dissolvable and 
swellable structures have, as indicated, many advantageous features but there is an assumption 
that their structure is wholly removed – either by dissolution or mechanical retrieval of the 
patch.  
The main cause for concern arises where there is incomplete dissolution or metabolism of the 
polymer constituents such that deposits are left within the skin [94]. It could also be theorized 
that the physical transformations that accompany swellable systems will necessarily weaken 
their attachment to the base plate of the plate and increase the possibility of fragmentation 
when removal is attempted. Given the latter are not designed for complete dissolution then this 
Chege et al Ulster University 16
th
 March 2016 
13 
 
could exacerbate irritation and stimulate the rich immune cell population of the skin [94,95]. In 
either case, it has been postulated that where there is repeated application of the patch (ie for 
insulin delivery), there is a possibility of polymer fragments being distributed and deposited 
throughout the skin which could be mobilised and result in hepatic accumulation [94,95]. As such, 
it could be expected that in some cases, the single use application of the patch is advised. 
 
6.0 Conclusions 
 
Most patients will display at least a degree of apprehension when faced with the need for a 
hypodermic injection but most will be unaware of the many safety issues that surround the 
handling, application and subsequent disposal of the syringe. Microneedles have evolved as a 
possible alternative which have been proven to dispel many of the patient’s concerns but there 
remain some issues over their use. Microneedles clearly have many advantages over 
conventional systems but they cannot be viewed as a total replacement as their dosage capacity 
is, by virtue of their design, considerably limited. As such, they are generally restricted to low 
yield high potency applications and have found ideal niche as vaccine delivery systems. The 
latter is particularly pertinent given the near universal reluctance of children to wilfully undergo 
injection, and it has been demonstrated that the more benign perception of the needle patch 
can actually enhance participation.  
 
While it is clear that microneedles hold considerable promise and commercial systems have 
begun to arise, the research effort that underpins the development processes can be lacking in a 
full appraisal of their safety. It is all too common to find research literature extolling the material 
benefits of a new microneedle design but with minimal appreciation of the need to clarify the 
failure stresses that can occur and the possible consequence of fracture fragmentation of the 
needle. Many of the failure stresses are conducted using conventional mechanical testing 
models rather than accurately simulating insertion within a more fluid epidermal layer and yet 
this is a crucial factor in ensuring safe administration and removal of the microneedle patch . 
Dissolvable needle systems are becoming more apparent and the self-disabling mechanism is a 
highly innovative approach to needlestick safety but there are still many questions as to the 
toxicological aspects of polymer residues being left in the skin and the consequence of polymer 
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fragments leaving the skin open to potential infection. Confirmation of successful delivery is 
often overlooked yet it is a critical requirement and the need for a simple feedback system is 
presently lacking.  
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Figure Legends 
 
Figure 1. Conventional transdermal patch assembly 
 
Figure 2. Mode of action inherent to solid (A), coated (B), hollow(C), dissolvable(D) and swellable (E) 
microneedle systems. 
 
Figure 3. SEM image of morphological change in microneedles with hydrogel microparticles regarding 
contact duration with PBS (a) 0 s, (b) 10 s, (c) 30 s, and (d) 60 s. SEM image of all microneedles broken 
mechanically after 60 s of contact (e). Microneedles were made of PLGA and 53% (v/v) of hydrogel 
particles were encapsulated in an array of microneedles. Reproduced from (75). 
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Figure 3. SEM image of morphological change in microneedles with hydrogel microparticles regarding 
contact duration with PBS (a) 0 s, (b) 10 s, (c) 30 s, and (d) 60 s. SEM image of all microneedles broken 
mechanically after 60 s of contact (e). Microneedles were made of PLGA and 53% (v/v) of hydrogel 
particles were encapsulated in an array of microneedles. Reproduced from (75). 
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Abstract 
 
Transdermal microneedles are regularly advocated as a much safer alternative to conventional 
hypodermic injections and an ever increasing range of systems are being developed. While there are 
clear advantages to their adoption, there are a number of safety issues that are emerging which 
have short and long term implications for patients, clinicians, healthcare administrators and 
regulators. A brief overview of microneedle design is presented and considered in a critical light in 
comparison to conventional drug delivery routes. The focus is not on drug safety but rather on the 
safety concerns of the actual delivery processes for patient and healthcare practitioner. The safety 
benefits that these new approaches offer and the potential safety concerns that still need to be 
addressed are highlighted and the possible implications critically assessed. 
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 Table 1. Commercial Transdermal Patches  
      
Year  Drug Application 
   
1979 Scopolamine Antisickness 
   
1984 Clonidine 
 
Hypertension 
1986 Estradiol 
 
Menopause symptoms 
1990 Fentanyl 
 
Acute post-operation pain 
1993 Testosterone 
 
Hypogonadism 
1995 Nitroglycerine 
 
Angina pectoris 
1996 
 
Nicotine 
 
Cigarette smoking cessation 
1999 Lidocaine 
 
Local anaesthetic 
2001 Enthinyl Estradiol 
w/Norelgestromin 
 
Contraceptive 
2003 Estradiol 
w/levonorgestrel 
 
Menopause symptoms 
2003 Oxybutin 
 
Overactive bladder 
2005 Lidocaine  
w/ tetracaine 
 
Local anaesthetic 
2006 Methylphenidate 
 
ADHD 
2006 Selegiline 
 
Depression 
2007 Diclofenac 
Epolamine 
 
Anti-inflammatory 
2007 Rivastigmine 
 
Dementia 
2007 Rotigotine 
 
Parkinson’s Disease 
2008 Granisteron 
 
Chemotherapy 
2013 Sumatriptan 
Succinate 
Antimigraine agent 
   
2014 Oxitriptan Depression 
 
    
1. Electronic Orange Book. (2016). Approved drug products with therapeutic equivalence 
evaluations 36th Edition. Available: http://www.fda.gov/default.htm. 
 
       
Table 2. Microneedle Composition, Design and Delivery 
        
Material                                               Type Drug/Vaccine Ref 
 
Silicon 
 
S 
 
BSA 
Insulin 
Ovalbumin(OVA) 
Rhodamine-labelled dextran 
Ethidium bromide 
Calcein 
 
 
 
1, 2 
 
Silicon 
 
S 
 
Meso-tetra( N-methyl-4-
pyridyl)porphine tetratosylate 
Plasmid DNA 
Galanthamine 
  
2 
 
 
 
 
Silicon S 5-aminolevulinic acid 
5-aminolevulinic acid methyl ester 
3 
 
Silicon 
 
C 
 
OVA protein vaccine 
Human Influenza vaccine 
rADV 
 
4 
    
Silicon  H Methyl nicotinate 
Hexyl nicotinate 
Influenza vaccine 
 
2,5 
Mesoporous Silicon S Ibuprofen  
Antipyrine Griseofulvin 
Ranitidine 
Furosemide 
6 
    
Metals    
    
Stainless Steel S Naltrexone 
Insulin 
Diptheria toxoid 
 
2 
Stainless Steel C Licodaine 
Vitamin B 
Calcein 
Luciferase 
Sulforhodamine 
Fluorescein 
Curcumin 
Cisplatin 
Modified Vaccinia virus Ankara 
Human IgG 
Salmon calcitonin 
2,4 
    
Titanium C rhGH 
OVA 
Desmopressin 
4 
Parathyroid hormone  
    
Nickel-Iron H Insulin 7 
    
Biodegradable polymers    
    
Poly-L-lactic Acid 
(PLA) 
D OVA 2, 8 
    
Polygycolic Acid 
(PGA) 
 
D 
C 
Human IgG 
Voriconazole 
2 
4 
Polylactide-co-glycolic Acid (PLGA) D 
 
Tetanus toxoid 
BSA 
Calcein 
2 
    
Polyvinylpyrrolidone (PVP) D Desmopressin 
BSA 
Influenza vaccine 
2 
    
Polyvinyl alcohol (PVA) 
 
D Sulforhodamine B 
 
2 
Polycarbonate S Calcein 2 
    
Non-biodegradable polymers    
    
Polyvinyl acetate (PVA) 
 
D Theophylline 9,10 
Alginic Acid 
 
D BSA 9,10 
Carbopol 971 P-NF 
 
D Theophylline 9,10 
Polycaprolactone D Doxorubicin hydrochloride 11 
    
Polysterene-block-Poly acrylic Acid 
 
SW Anti-scarring agents/antibiotics 12 
Poly(methyl vinyl ether-co-maleic anhydride) 
 
C Miconazole 
Parathyroid hormone 
4 
Polyethylene gycol (PEG) 
 
C Licodaine 4 
Poly[di(carboxylatophenoxy)phosphazene] 
 
C Hepatitis B vaccine 10 
Plastic S Chimeric flavivirus vaccine 
Anthrax vaccine 
Rabies vaccine 
Influenza vaccine 
2 
    
Natural polymers    
    
Thermoplastic starch D Tetanus toxoid 1, 13 
    
Carboxymethylcellulose D Insulin 8, 13 
Sulforhodamine B 
Lidocaine HCl 
    
Amylopectin D 
 
Sulforhodamine B 2 
Dextran D LMW Heparin 
Erythropoietin 
rhGH 
 
2, 14 
Chondroitin sulphate D LMW Heparin 
Erythropoietin 
rhGH 
Leuprolide acetate 
2, 14 
    
Galactose D 5-aminolevulinic acid 
BSA 
2, 14 
    
Maltose D 
S 
 S 
D 
Human IgG 
Nicardipine hydrochloride 
Methotraxate 
LMW Heparin 
14, 15 
    
Ceramics    
    
Aluminium Oxide 
Alumina and zirconia 
NP 
H 
 
Vaccines  
 
2, 16 
    
        
Glass H Sulforhodamine B 
Insulin 
2 
        
Where: S = solid; C = coated; H = hollow; D = dissolvable; SW = swellable; NP= nanoporous; rADV= recombinant human 
adenovirus; IgG= human immunoglobulin; BSA= bovine serum albumin; LMW= low molecular weight; rhGH= 
recombinant human growth hormone. 
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